Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.


Usul A., KARABULUT M., KARABULUT S., ALıS H., GONENC M., DAGOGLU N., ...Daha Fazla

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, cilt.23, ss.196-200, 2017 (SCI-Expanded) identifier identifier identifier